<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290717</url>
  </required_header>
  <id_info>
    <org_study_id>NL45970.018.13</org_study_id>
    <nct_id>NCT02290717</nct_id>
  </id_info>
  <brief_title>Fractional Laser in Combination With UVB Therapy in Vitiligo Patients</brief_title>
  <official_title>Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Netherlands Institute for Pigment Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Netherlands Institute for Pigment Disorders</source>
  <brief_summary>
    <textblock>
      Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life.
      Many depigmented lesions in vitiligo patients remain therapy resistant for medical treatment.
      Therefore new therapeutic options in these patients are necessary. Currently, dermabrasion by
      conventional or fractional laser therapy in combination with NB-UVB therapy and steroids
      appears to be effective in therapy resistant areas. However, little literature on this
      combination is available.

      Objectives: To assess the efficacy and patient safety of (1)fractional CO2-laser treatment in
      combination with NB- UVB,(2) fractional CO2-laser treatment in combination with NB- UVB and
      topical corticosteroids versus NB-UVB treatment alone(3) Study design: Prospective observer
      blinded randomised intra-patient controlled study.

      Study population: 23 patients ≥ 18 years with non segmental vitiligo who receive NB-UVB
      treatment at the Netherlands Institute for Pigment Disorders (SNIP) at the Academic Medical
      Centre University of Amsterdam. We will include patients with 3 depigmented lesions that are
      resistant to NB- UVB treatment after 3 to 6 months.

      Methods: Three NB-UVB resistant depigmented regions on the trunk or extremities will be
      randomly allocated to;(1) NB-UVB treatment in combination with fractional CO2 laser abrasion,
      or (2) NB-UVB treatment in combination with fractional CO2 laser abrasion and topical
      steroids, or (3) NB-UVB treatment alone. NB-UVB treatment and topical steroids will be given
      according to the standard treatment protocol of the SNIP and continued for at least 6 months.
      Two and 6 months after the laser treatment, the percentage of repigmentation of the lesions
      will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulty including patients
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation % with sheets</measure>
    <time_frame>6 mo after treatment</time_frame>
    <description>% of repigmentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment physician</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment patient</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual assessment of hyperpigmentation/hypopigmentation/scar formation</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of repigmentation physician</measure>
    <time_frame>6months after treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months after treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Color difference between erythema and (re)pigmentation</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>with a Derma-spectrometer the difference between erythema and (re)pigmentation will be assessed.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Laser+fluticason+UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser+UVB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UVB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional CO2 laser</intervention_name>
    <arm_group_label>Laser+fluticason+UVB</arm_group_label>
    <arm_group_label>Laser+UVB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NB-UVB therapy</intervention_name>
    <description>NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.</description>
    <arm_group_label>Laser+fluticason+UVB</arm_group_label>
    <arm_group_label>Laser+UVB</arm_group_label>
    <arm_group_label>UVB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate Cream 0.05%</intervention_name>
    <description>4 times a week (standard IPD protocol)</description>
    <arm_group_label>Laser+fluticason+UVB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Patients with non segmental (generalised) vitiligo visiting the Netherlands Institute
             for Pigment Disorders

          -  receiving NB- UVB treatment for 3 to 6 months

          -  Age &gt;18 years

          -  At least 3 therapy resistant vitiligo lesions on the extremities or trunk larger than
             5x5 cm or one vitiligo lesion on the extremities or trunk of at least 5x15 cm.

          -  Patient is willing and able to give written informed consent

        Exclusion criteria

          -  Skin type I

          -  Recurrent HSV skin infections

          -  Hypertrophic scars

          -  Keloid

          -  Cardial insufficiency

          -  Patients who are pregnant or breast-feeding

          -  Patients not competent to understand what the procedures involved

          -  Patients with a personal history of melanoma or non-melanoma skin cancer

          -  Patients with atypical nevi.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Garg T, Chander R, Jain A. Combination of microdermabrasion and 5-fluorouracil to induce repigmentation in vitiligo: an observational study. Dermatol Surg. 2011 Dec;37(12):1763-6. doi: 10.1111/j.1524-4725.2011.02127.x. Epub 2011 Aug 11.</citation>
    <PMID>21834930</PMID>
  </reference>
  <reference>
    <citation>Shin J, Lee JS, Hann SK, Oh SH. Combination treatment by 10 600 nm ablative fractional carbon dioxide laser and narrowband ultraviolet B in refractory nonsegmental vitiligo: a prospective, randomized half-body comparative study. Br J Dermatol. 2012 Mar;166(3):658-61. doi: 10.1111/j.1365-2133.2011.10723.x. Epub 2012 Jan 19.</citation>
    <PMID>22050270</PMID>
  </reference>
  <reference>
    <citation>Bayoumi W, Fontas E, Sillard L, Le Duff F, Ortonne JP, Bahadoran P, Lacour JP, Passeron T. Effect of a preceding laser dermabrasion on the outcome of combined therapy with narrowband ultraviolet B and potent topical steroids for treating nonsegmental vitiligo in resistant localizations. Br J Dermatol. 2012 Jan;166(1):208-11. doi: 10.1111/j.1365-2133.2011.10564.x. Epub 2011 Nov 17.</citation>
    <PMID>21824124</PMID>
  </reference>
  <reference>
    <citation>Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JP. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009 Sep;61(3):411-20. doi: 10.1016/j.jaad.2009.03.022. Epub 2009 Jul 3.</citation>
    <PMID>19577331</PMID>
  </reference>
  <reference>
    <citation>Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005 Jun;152(6):1165-72.</citation>
    <PMID>15948977</PMID>
  </reference>
  <reference>
    <citation>Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011 Sep;65(3):473-91. doi: 10.1016/j.jaad.2010.11.061. Review.</citation>
    <PMID>21839315</PMID>
  </reference>
  <reference>
    <citation>Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Turner ML, Webster SB, Whitaker DC, Lowery BJ, Nordlund JJ, Grimes PE, Halder RM, Minus HR. Guidelines of care for vitiligo. American Academy of Dermatology. J Am Acad Dermatol. 1996 Oct;35(4):620-6.</citation>
    <PMID>8859294</PMID>
  </reference>
  <reference>
    <citation>Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167-81. Review.</citation>
    <PMID>11705094</PMID>
  </reference>
  <reference>
    <citation>Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. doi: 10.1056/NEJMcp0804388. Review.</citation>
    <PMID>19129529</PMID>
  </reference>
  <reference>
    <citation>Taieb A, Alomar A, Böhm M, Dell'anna ML, De Pase A, Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger DJ, Jouary T, Leone G, Moretti S, Nieuweboer-Krobotova L, Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europe´enne des Me´decins Spe´cialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19. doi: 10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2.</citation>
    <PMID>22860621</PMID>
  </reference>
  <reference>
    <citation>Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, Hercogova J. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008 Jul;21 Suppl 1:S20-6. doi: 10.1111/j.1529-8019.2008.00198.x.</citation>
    <PMID>18727812</PMID>
  </reference>
  <reference>
    <citation>Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009 May-Jun;26(3):286-91. doi: 10.1111/j.1525-1470.2009.00926.x.</citation>
    <PMID>19706089</PMID>
  </reference>
  <reference>
    <citation>van Geel N, Ongenae K, Naeyaert JM. Surgical techniques for vitiligo: a review. Dermatology. 2001;202(2):162-6. Review.</citation>
    <PMID>11306848</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Netherlands Institute for Pigment Disorders</investigator_affiliation>
    <investigator_full_name>JELommerts</investigator_full_name>
    <investigator_title>MSc MD</investigator_title>
  </responsible_party>
  <keyword>ultraviolet therapy</keyword>
  <keyword>non segmental</keyword>
  <keyword>vitiligo</keyword>
  <keyword>topical corticosteroid</keyword>
  <keyword>laser</keyword>
  <keyword>fractional</keyword>
  <keyword>CO2</keyword>
  <keyword>carbon dioxide</keyword>
  <keyword>UVB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

